Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified
Conditions
Interventions
None listed
Sponsors
ICMR
Eligibility
Inclusion criteria
Inclusion criteria: Diagnosed cases of MASLD of either sex in the age group of 30 – 60 years will be included for the study
Exclusion criteria
Exclusion criteria: Patients diagnosed of any other forms of liver diseases like hepatitis, cirrhosis, HCC; patients taking long term hepatotoxic medications like NSAID, rifampicin, corticosteroids or already taking supplementary medicines for fatty liver, patients consuming tobacco, alcohol or any other narcotic substances, pregnant or lactating women or any other condition which may jeopardize the study will be excluded from the trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes In FIB-4 Score, CLDQ - MASH, Fat Attenuation Value Measured Through USAT, Liver Stiffness Value Measured Through Shear Wave Elastography of MASLD patientsTimepoint: Baseline, 29th day, 57th day, 85th day | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in LFT, lipid profile, inflammatory markers (CRP, IL-6, TNF – alpha), gut microbiome studies (16S rRNA Sequencing), metabolomic profiling of fecal and plasma samples and Fecal Short chain fatty acid (SCFA) profilingTimepoint: Baseline, 85th day | — |
Countries
India
Contacts
Public ContactDr Remya E
Central Ayurveda Research Institute, Bhubaneswar, CCRAS
Outcome results
None listed